ArticleDiagnostics (Basel, Switzerland)2023

Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study.

Filipa Curado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.